Where it's made
| Factory | Where | Role | Last FDA inspection |
|---|---|---|---|
| Roche Singapore Technical Operations Pte. Ltd. | Singapore, Singapore | Makes the active ingredient and tests it | Problems found, fixed voluntarilyNov 14, 2025 · 6 inspections |
| Genentech, Inc. | Hillsboro, OR, United States | Tests it, packages it and labels it | Problems found, fixed voluntarilyApr 19, 2024 · 7 inspections |
| Roche Diagnostics GmbH | Mannheim, Germany | Tests it | Problems found, fixed voluntarilyOct 29, 2021 · 5 inspections |
Recalls
- Oct 18, 2022 · Class III · Genentech Inc
Defective Delivery System: Commercial implants do not meet the filed specification for the intended use, a few patients have experienced an issue with the implants that renders it non-functioning.
Lots: Lot/Exp: a) 3499188, Exp 10/31/2022; Lot 3523071, Exp 6/30/2023; b) 3456735, Exp 10/23/2026; 3456737; Exp 10/29/2026; 3477671, Exp 10/31/2026; 3480781, Exp 12/19/2026; 3506526, Exp 02/25/2027; 3506531, Exp 04/15/2027
Class I recalls are the most serious; Class III the least. A recall covers specific lots, listed on each recall.
Product details
- Generic drug
- Ranibizumab: every company that makes it
- Form
- injection, solution, intravitreal
- Strength
- 100 mg per 1 mL
- Approval
- BLA BLA761197
- On the market since
- Oct 22, 2021
- Package NDCs
50242-078-1250242-078-55- Official label
- DailyMed (National Library of Medicine), updated Nov 21, 2025
Got it by mail or from a pharmacy you don't know? Look the pharmacy up on Who Filled My Rx?